ClinicalTrials.Veeva

Menu
R

Retinal Consultants Medical Group | Greenback Lane, Sacramento, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

KSI-301
Faricimab
Elamipretide
BI 764524
Iptacopan
OPL-0401
Tarcocimab
AU-011
Aflibercept
AVD-104

Parent organization

This site is a part of Retinal Consultants Medical Group

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 15 total trials

A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration

The purpose of this study is to assess the effect of Iptacopan to prevent conversion of early or intermediate age-related macular degeneration (AMD)...

Enrolling
Age-Related Macular Degeneration
Drug: Placebo
Drug: Iptacopan (LNP023)

Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atro...

Enrolling
Macular Degeneration
Geographic Atrophy of the Macula
Drug: AVD-104
Drug: Avacincaptad

The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary i...

Enrolling
Indeterminate Lesions
Ocular Melanoma
Device: Suprachoroidal Microinjector
Drug: Sham Treatment

This study will demonstrate that tarcocimab 5 mg is superior to sham treatment in participants with moderately severe to severe NPDR.

Enrolling
Non-proliferative Diabetic Retinopathy
Drug: Tarcocimab
Other: Sham injection

This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treat...

Enrolling
Diabetic Macular Edema
Drug: Faricimab

This study will evaluate the success and safety of subretinal surgical delivery as well as the preliminary activity of OpRegen in participants with g...

Enrolling
Geographic Atrophy
Biological: OpRegen

This study is open to adults with diabetic retinopathy. People who have non-proliferative diabetic retinopathy of moderate or high severity can join...

Enrolling
Diabetic Retinopathy
Drug: BI 764524
Drug: Aflibercept (Eylea®) - US only

OPL-0401-201 is a multicenter study to investigate the safety and efficacy of OPL-0401 in patients with diabetes mellitus (DM) with diabetic retinopa...

Active, not recruiting
Non-proliferative Diabetic Retinopathy
Proliferative Diabetic Retinopathy
Drug: Placebo
Drug: OPL-0401 Dose 1

The goal of this clinical trial is to evaluate the efficacy, safety and pharmacokinetics of elamipretide in subjects with dry age-related macular deg...

Enrolling
Age-Related Macular Degeneration
Drug: Elamipretide
Drug: Placebo

Trial sponsors

Kodiak Sciences logo
Genentech logo
Aura Biosciences logo
A
Bayer logo
Boehringer Ingelheim logo
Novartis logo
Roche logo
Stealth BioTherapeutics logo
V

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems